Distal technologies and type 1 diabetes management

Danny Duke, Samantha Barry, David V. Wagner, Jane Speight, Pratik Choudhary, Michael Harris

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Type 1 diabetes requires intensive self-management to avoid acute and long-term health complications. In the past two decades, substantial advances in technology have enabled more effective and convenient self-management of type 1 diabetes. Although proximal technologies (eg, insulin pumps, continuous glucose monitors, closed-loop and artificial pancreas systems) have been the subject of frequent systematic and narrative reviews, distal technologies have received scant attention. Distal technologies refer to electronic systems designed to provide a service remotely and include heterogeneous systems such as telehealth, mobile health applications, game-based support, social platforms, and patient portals. In this Review, we summarise the empirical literature to provide current information about the effectiveness of available distal technologies to improve type 1 diabetes management. We also discuss privacy, ethics, and regulatory considerations, issues of global adoption, knowledge gaps in distal technology, and recommendations for future directions.

Original languageEnglish (US)
JournalThe Lancet Diabetes and Endocrinology
DOIs
StateAccepted/In press - 2017

Fingerprint

Type 1 Diabetes Mellitus
Technology
Telemedicine
Self Care
Artificial Pancreas
Mobile Applications
Privacy
Ethics
Insulin
Glucose
Health

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Distal technologies and type 1 diabetes management. / Duke, Danny; Barry, Samantha; Wagner, David V.; Speight, Jane; Choudhary, Pratik; Harris, Michael.

In: The Lancet Diabetes and Endocrinology, 2017.

Research output: Contribution to journalArticle

Duke, Danny ; Barry, Samantha ; Wagner, David V. ; Speight, Jane ; Choudhary, Pratik ; Harris, Michael. / Distal technologies and type 1 diabetes management. In: The Lancet Diabetes and Endocrinology. 2017.
@article{5d0cf76b2fe64c55a46a68f43ed04ae6,
title = "Distal technologies and type 1 diabetes management",
abstract = "Type 1 diabetes requires intensive self-management to avoid acute and long-term health complications. In the past two decades, substantial advances in technology have enabled more effective and convenient self-management of type 1 diabetes. Although proximal technologies (eg, insulin pumps, continuous glucose monitors, closed-loop and artificial pancreas systems) have been the subject of frequent systematic and narrative reviews, distal technologies have received scant attention. Distal technologies refer to electronic systems designed to provide a service remotely and include heterogeneous systems such as telehealth, mobile health applications, game-based support, social platforms, and patient portals. In this Review, we summarise the empirical literature to provide current information about the effectiveness of available distal technologies to improve type 1 diabetes management. We also discuss privacy, ethics, and regulatory considerations, issues of global adoption, knowledge gaps in distal technology, and recommendations for future directions.",
author = "Danny Duke and Samantha Barry and Wagner, {David V.} and Jane Speight and Pratik Choudhary and Michael Harris",
year = "2017",
doi = "10.1016/S2213-8587(17)30260-7",
language = "English (US)",
journal = "The Lancet Diabetes and Endocrinology",
issn = "2213-8587",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Distal technologies and type 1 diabetes management

AU - Duke, Danny

AU - Barry, Samantha

AU - Wagner, David V.

AU - Speight, Jane

AU - Choudhary, Pratik

AU - Harris, Michael

PY - 2017

Y1 - 2017

N2 - Type 1 diabetes requires intensive self-management to avoid acute and long-term health complications. In the past two decades, substantial advances in technology have enabled more effective and convenient self-management of type 1 diabetes. Although proximal technologies (eg, insulin pumps, continuous glucose monitors, closed-loop and artificial pancreas systems) have been the subject of frequent systematic and narrative reviews, distal technologies have received scant attention. Distal technologies refer to electronic systems designed to provide a service remotely and include heterogeneous systems such as telehealth, mobile health applications, game-based support, social platforms, and patient portals. In this Review, we summarise the empirical literature to provide current information about the effectiveness of available distal technologies to improve type 1 diabetes management. We also discuss privacy, ethics, and regulatory considerations, issues of global adoption, knowledge gaps in distal technology, and recommendations for future directions.

AB - Type 1 diabetes requires intensive self-management to avoid acute and long-term health complications. In the past two decades, substantial advances in technology have enabled more effective and convenient self-management of type 1 diabetes. Although proximal technologies (eg, insulin pumps, continuous glucose monitors, closed-loop and artificial pancreas systems) have been the subject of frequent systematic and narrative reviews, distal technologies have received scant attention. Distal technologies refer to electronic systems designed to provide a service remotely and include heterogeneous systems such as telehealth, mobile health applications, game-based support, social platforms, and patient portals. In this Review, we summarise the empirical literature to provide current information about the effectiveness of available distal technologies to improve type 1 diabetes management. We also discuss privacy, ethics, and regulatory considerations, issues of global adoption, knowledge gaps in distal technology, and recommendations for future directions.

UR - http://www.scopus.com/inward/record.url?scp=85028588394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028588394&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(17)30260-7

DO - 10.1016/S2213-8587(17)30260-7

M3 - Article

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

ER -